Zhejiang Garden Biopharmaceutical Co.,Ltd.

Equities

300401

CNE100001XX7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
10.79 CNY -1.64% Intraday chart for Zhejiang Garden Biopharmaceutical Co.,Ltd. +1.12% -8.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Garden Biopharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Garden Biopharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on September 14, 2023. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s Equity Buyback announced on September 14, 2023, has completed with 9,307,200 shares, representing 1.7% for CNY 100 million. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. Announces Board Appointments CI
Zhejiang Garden Biopharmaceutical's Unit Gets Nod for Eight New Products MT
Tranche Update on Zhejiang Garden Biopharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on September 14, 2023. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Zhejiang Garden Biopharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on September 14, 2023. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on September 7, 2023. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
Zhejiang Garden Biopharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Garden Biopharma Registers Acid Reflux Drug MT
Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 24, 2023 CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. has Changed its Name to Zhejiang Garden Biopharmaceutical Co., Ltd CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. announced a financing transaction CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. Announces 2021 Final Cash Profit Distribution Plan on A Shares, Payable on 18 May 2022 CI
Zhejiang Garden Bio-Chemical High-Tech Co., Ltd. Approves Final Cash Dividend for the Year 2021 CI
Zhejiang Garden Bio-chemical High-tech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Zhejiang Garden Biopharmaceutical Co.,Ltd.
More charts
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300401 Stock
  4. News Zhejiang Garden Biopharmaceutical Co.,Ltd.
  5. Zhejiang Garden Biopharmaceutical's Unit Gets Nod for Eight New Products